274 related articles for article (PubMed ID: 9384224)
1. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
2. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
Gupta P; Butler P; Shepperson NB; McHarg A
Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
[TBL] [Abstract][Full Text] [Related]
3. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
4. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
[TBL] [Abstract][Full Text] [Related]
5. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Heiligers JP; Bax WA; Maassen VanDenBrink A; Yocca FD
Eur J Pharmacol; 1998 Jun; 351(3):329-39. PubMed ID: 9721025
[TBL] [Abstract][Full Text] [Related]
6. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.
Buzzi MG; Moskowitz MA; Peroutka SJ; Byun B
Br J Pharmacol; 1991 Jun; 103(2):1421-8. PubMed ID: 1653072
[TBL] [Abstract][Full Text] [Related]
7. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
8. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Yu XJ; Cutrer FM; Moskowitz MA; Waeber C
Neuropharmacology; 1997 Jan; 36(1):83-91. PubMed ID: 9144644
[TBL] [Abstract][Full Text] [Related]
9. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype.
Perren MJ; Feniuk W; Humphrey PP
Br J Pharmacol; 1991 Jan; 102(1):191-7. PubMed ID: 1675143
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
McCall RB; Huff R; Chio CL; TenBrink R; Bergh CL; Ennis MD; Ghazal NB; Hoffman RL; Meisheri K; Higdon NR; Hall E
Cephalalgia; 2002 Dec; 22(10):799-806. PubMed ID: 12485205
[TBL] [Abstract][Full Text] [Related]
11. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
Ellwood AJ; Curtis MJ
Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
[TBL] [Abstract][Full Text] [Related]
12. Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses.
Dupuis DS; Perez M; Halazy S; Colpaert FC; Pauwels PJ
Brain Res Mol Brain Res; 1999 Apr; 67(1):107-23. PubMed ID: 10101238
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
14. Operational characteristics of the 5-HT1-like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Close resemblance to the 5-HT1D receptor subtype.
Villalón CM; Sánchez-López A; Centurión D
Naunyn Schmiedebergs Arch Pharmacol; 1996 Nov; 354(5):550-6. PubMed ID: 8938651
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses.
De Vries P; Willems EW; Heiligers JP; Villalón CM; Saxena PR
Br J Pharmacol; 1999 May; 127(2):405-12. PubMed ID: 10385240
[TBL] [Abstract][Full Text] [Related]
16. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
17. The 5-HT1-like receptor mediating the increase in canine external carotid blood flow: close resemblance to the 5-HT1D subtype.
Villalón CM; Terrón JA
Br J Pharmacol; 1994 Sep; 113(1):13-20. PubMed ID: 7812603
[TBL] [Abstract][Full Text] [Related]
18. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.
Gupta P; Brown D; Butler P; Ellis P; Grayson KL; Land GC; Macor JE; Robson SF; Wythes MJ; Shepperson NB
Br J Pharmacol; 1995 Nov; 116(5):2385-90. PubMed ID: 8581273
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
20. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor.
Jansen I; Edvinsson L; Mortensen A; Olesen J
Cephalalgia; 1992 Aug; 12(4):202-5. PubMed ID: 1326402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
